Telomir Pharmaceuticals

TELO

Market cap $85.3M

TELO Hedge Fund Activity: Q1 2026 in Review

27 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q1 2026, worth a combined $2.91M — down 4.2% from $3.04M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of TELO and 5 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Geode Capital Management, adding an estimated $32.6K. The largest seller was Millennium Management, cutting an estimated $48.4K.

• 27 institutional investors held Telomir Pharmaceuticals (TELO) as of Q1 2026, down from 33 in Q4 2025.
• Funds reported $2.91M of Telomir Pharmaceuticals stock for Q1 2026, down 4.2% quarter-over-quarter.
• 5 funds opened new Telomir Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of -5 holders.
• The largest Telomir Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $32.6K added.
• The largest Telomir Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $48.4K sold.

Based on aggregated 13F filings for Q1 2026.